Metabolon Collaborates with The Michael J. Fox Foundation to Advance Multiomic Analyses for Parkinson’s Research
Partnership supports expanded biomarker discovery efforts within MJFF's Parkinson's Progression Markers InitiativeMORRISVILLE,…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results…
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the -synuclein PET tracer 18F-FD4 for Parkinson’s disease
NEW HAVEN, Conn., Sept. 10, 2025 /PRNewswire/ -- XingImaging in partnership with…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
